LXR agonist treatment of blastic plasmacytoid dendritic cell neoplasm restores cholesterol efflux and triggers apoptosis

Blastic plasmacytoid dendritic cell (PDC) neoplasm (BPDCN) is an aggressive hematological malignancy with a poor prognosis that derives from PDCs. No consensus for optimal treatment modalities is available today and the full characterization of this leukemia is still emerging. We identified here a B...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Blood
Autores principales: Ceroi, Adam, Masson, David, Roggy, Anne, Roumier, Christophe, Chagué, Cécile, Gauthier, Thierry, Philippe, Laure, Lamarthée, Baptiste, Angelot-Delettre, Fanny, Bonnefoy, Francis, Perruche, Sylvain, Biichle, Sabeha, Preudhomme, Claude, Macintyre, Elisabeth, Lagrost, Laurent, Garnache-Ottou, Francine, Saas, Philippe
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2016
Materias:
Myeloid Neoplasia
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5271175/
https://ncbi.nlm.nih.gov/pubmed/27702801
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-06-724807
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares